Drug Trial Radar · NCT06307522
MRG-001 in Patients With Alcoholic Hepatitis
Last checked: Nov 20, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Sep 1, 2024
Primary completion
Sep 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- MedRegen LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH).
Conditions
- Alcoholic Hepatitis
- Acute Alcoholic Hepatitis
Interventions
MRG-001Drug
Patients will receive subcutaneous administration of MRG-001 at designated visits.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Treatment-Emergent Adverse EventsTime frame: 28 Days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.